The vision of the Sustainable Development Goals (SDG) is to achieve a better and more sustainable future for all. In the past years, although in the absence of cure or vaccines, the treatment of HIV infection with combination Antiretroviral Therapy (cART) has been pretty successful. Despite this, long term HIV infection is associated with an enhanced and accentuated onset of non-AIDS-related pathologies. For different and not completely defined reasons, long-term treated HIV-infected individuals suffer from some age-related maladies due to chronic inflammation and immune activation during the cART. With aging, a progressive inflammatory state causes chronic, low-grade systemic inflammation that, in HIV patients, ultimately triggers the development of several age-related non-infectious comorbidities (NICMs). In HIV infection, it is believed that viral persistence in a rare population of long-lived, latently infected cells that survive in spite of suppressive ART, contributes to the chronic inflammatory state.
Systems biology approaches have been increasingly implemented in biomedical research over the last years and are helping in getting a more complete understanding of which genetic and environmental factors affect the complexities of human aging. Application of -omics to understand the mechanisms of immune aging in people living with HIV (PLHIV) in the era of effective ART might be beneficial not only for their wellness, but also to understand the mechanisms of immune aging in healthy subjects.
In this Research Topic we aim to explore the knowledge obtained from recent scientific advances and cutting-edge technologies in the broad field of immune aging and HIV. We welcome the submission of Original Research articles, Reviews, Methods, Clinical Trials and Perspectives focused on the following subtopics:
• Omics studies (transcriptomics, proteomics, metabolomics) to understand immune aging in PLHIV
• Use of soluble biomarkers to define inflammatory state in PLHIV
• Mechanistic studies to understand the immune-aging in PLHIV
• Clinical trials/studies related to the aging in PLHIV
The vision of the Sustainable Development Goals (SDG) is to achieve a better and more sustainable future for all. In the past years, although in the absence of cure or vaccines, the treatment of HIV infection with combination Antiretroviral Therapy (cART) has been pretty successful. Despite this, long term HIV infection is associated with an enhanced and accentuated onset of non-AIDS-related pathologies. For different and not completely defined reasons, long-term treated HIV-infected individuals suffer from some age-related maladies due to chronic inflammation and immune activation during the cART. With aging, a progressive inflammatory state causes chronic, low-grade systemic inflammation that, in HIV patients, ultimately triggers the development of several age-related non-infectious comorbidities (NICMs). In HIV infection, it is believed that viral persistence in a rare population of long-lived, latently infected cells that survive in spite of suppressive ART, contributes to the chronic inflammatory state.
Systems biology approaches have been increasingly implemented in biomedical research over the last years and are helping in getting a more complete understanding of which genetic and environmental factors affect the complexities of human aging. Application of -omics to understand the mechanisms of immune aging in people living with HIV (PLHIV) in the era of effective ART might be beneficial not only for their wellness, but also to understand the mechanisms of immune aging in healthy subjects.
In this Research Topic we aim to explore the knowledge obtained from recent scientific advances and cutting-edge technologies in the broad field of immune aging and HIV. We welcome the submission of Original Research articles, Reviews, Methods, Clinical Trials and Perspectives focused on the following subtopics:
• Omics studies (transcriptomics, proteomics, metabolomics) to understand immune aging in PLHIV
• Use of soluble biomarkers to define inflammatory state in PLHIV
• Mechanistic studies to understand the immune-aging in PLHIV
• Clinical trials/studies related to the aging in PLHIV